Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 6, 2008, Pages 723-730

  Okumura, Takako ^a,b   Murata, Yoko ^a   Taniguchi, Kana ^a   Murase, Akio ^a   Nii, Aisuke ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CJ 023423; GLOBULIN; N [[[2 [4 (2 ETHYL 4,6 DIMETHYL 1H IMIDAZO[4,5 C]PYRIDIN 1 YL)PHENYL]ETHYL]AMINO]CARBONYL] 4 METHYLBENZENESUFLONAMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 EP4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; ROFECOXIB; SIALIC ACID; ANTIINFLAMMATORY AGENT; CJ 023,423; CJ-023,423; LACTONE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; SULFONAMIDE; SULFONE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE EROSION; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; EXTRAVASATION; HISTOPATHOLOGY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATHOGENESIS; PAW EDEMA; POLYARTHRITIS; PROTEIN BLOOD LEVEL; RAT; RECEPTOR BLOCKING; SYNOVITIS; ANIMAL; ARTHRITIS; COMPARATIVE STUDY; DRUG ANTAGONISM; EDEMA; INFLAMMATION; LEWIS RAT; METABOLISM; OSTEOLYSIS; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; INFLAMMATION; LACTONES; MALE; RATS; RATS, INBRED LEW; RECEPTORS, PROSTAGLANDIN E; SULFONAMIDES; SULFONES;

EID: 43949117744     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.6.0007     Document Type: Article

References (23)

1. Anderson, G. D., Hauser, S. D., McGarity, K. L., Bremer, M. E., Isakson, P. C., Gregory, S. A. (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97: 2672-2679
2. Basu, S. (2006) Novel cyclooxygenase-catalyzed bioactive prostaglandin F(2alpha) from physiology to new principles in inflammation. Med. Res. Rev. 27: 435-468
3. Breyer, R. M., Bagdassarian, C. K., Myers, S. A., Breyer, M. D. (2001) Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41: 661-690
4. Campagnuolo, G., Bolon, B., Feige, U. (2002) Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum. 46: 1926-1936
5. Coleman, R. A., Smith, W. L., Narumiya, S. (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46: 205-229
6. Harirforoosh, S., Aghazadeh-Habashi, A., Jamali, F. (2006) Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetics dependent. Clin. Exp. Pharmacol. Physiol. 33: 917-924
7. Honda, T., Segi-Nishida, E., Miyachi, Y., Narumiya, S. (2006) Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J. Exp. Med. 203: 325-335
8. Kourounakis, L., Gavalas, A., Karagouni, E. E., Litina, D., Kourounakis, P. (1991) Anti-inflammatory and immunomodulating effects of the novel agent gamma-(2-aminoethylamino)-2-butyrothienone. 2nd communication: inhibitory effect on rat adjuvant induced disease. Arzneimittelforschung 41: 537-541
9. McCoy, J. M., Wicks, J. R., Audoly, L. P. (2002) The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110: 651-658
10. Nakao, K., Murase, A., Ohshiro, H., Okumura, T., Taniguchi, K., Murata, Y., Masuda, M., Kato, T., Okumura, Y., Takada, J. (2007) CJ-023,423 (N-[({2-[4-(2-ethyl-4, 6-dimethyl-1H-imidazo [4, 5-c] Pyridin-1-yl) phenyl] ethyl} amino) carbonyl]-4-methylbenzenesulfonamide), a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J. Pharmacol. Exp. Ther. 322: 686-694
11. Narumiya, S., Sugimoto, Y., Ushikubi, F. (1999) Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226
12. Omote, K., Kawamata, T., Nakayama, Y., Yamamoto, H., Kawamata, M., Namiki, A. (2002) Effects of a novel selective agonist for prostaglandin receptor subtype EP4 on hyperalgesia and inflammation in monoarthritic model. Anesthesiology 97: 170-176
13. Ono, K., Akatsu, T., Murakami, T., Nishikawa, M., Yamamoto, M., Kugai, N., Motoyoshi K., Nagata, N. (1998) Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2. J. Endocrinol. 158: R1-R5
14. Portanova, J. P., Zhang Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., Seibert, K., Gregory, S. A., Isakson, P. C. (1996) Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184: 883-891
15. Pulichino, A. M., Rowland, S., Wu, T., Clark, P., Xu, D., Mathieu, M. C., Riendeau, D., Audoly, L. P. (2006) Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J. Pharmacol. Exp. Ther. 319: 1043-1050
16. Schett, G., Redlich, K., Smolen, J. S. (2003) The role of osteoprotegerin in arthritis. Arthritis Res. Ther. 5: 239-245
17. Takita, M., Inada, M., Maruyama, T., Miyaura, C. (2007) Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells. FEBS Lett. 581: 565-571
18. Tanahashi, M., Funaba, Y., Itoh, M., Kawabe, N., Nakadate-Matsushita, T. (1998) Inhibitory effects of TRK-530 on rat adjuvant arthritis. Pharmacology 56: 242-251
19. Taurog, J. D., Argentieri, D. C., McReynolds, R. A. (1988) Adjuvant arthritis. Methods Enzymol 162: 339-355
20. Tomita, M., Li, X., Okada, Y., Woodiel, F. N., Young, R. N., Pilbeam, C. C., Raisz, L. G. (2002) Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 30: 159-163
21. Van Eden, W., Waksman, B. H. (2003) Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis. Arthritis Rheum 48: 1788-1796
22. Wilson, R. J., Giles, H. (2005) Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br. J. Pharmacol. 144: 405-415
23. Wilson, R. J., Giblin, G. M., Roomans, S., Rhodes, S. A., Cartwright, K. A., Shield, V. J., Brown, J., Wise, A., Chowdhury, J., Pritchard, S., Coote, J., Noel, L. S., Kenakin, T., Burns-Kurtis, C. L., Morrison, V., Gray, D. W., Giles, H. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f] isoindol-2-yl)phenyl] acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br. J. Pharmacol. 148: 326-339